University Of California Los Angeles

Women with lower levels of anti-Müllerian hormone may experience greater bone loss during menopause transition, according to study findings published in the Journal of Bone and Mineral Research.

Cancer centers, advocacy groups and other organizations have ramped up efforts to reduce disparities across the cancer care continuum, according to presenters at the virtual National Comprehensive Cancer Network 2022 Annual Conference.

In a new study, patients with COVID-19-associated respiratory failure who required mechanical ventilation had a better chance of recovery than patients without COVID-19, due to improved ventilator liberation and physical functioning.

CHICAGO — According to a presenter at the American Academy of Orthopaedic Surgeons Annual Meeting, athletes returning to competition in their first season after the COVID-19 pandemic were at higher risk for noncontact and overuse injury.

Just as physicians became accustomed to wearing pagers 40 years ago or being tied to smartphones 2 decades ago, many have become active on social media as it entered their practices.

Nintedanib reduces the rate of forced vital capacity decline more significantly in patients with systemic sclerosis-associated interstitial lung disease who reported no dyspnea or cough at baseline, data show.

Although Black men presented with more aggressive prostate cancer, they experienced better outcomes with definitive radiotherapy compared with white men, according to results of a meta-analysis published in JAMA Network Open.

American Association for Cancer Research released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and research practice.

Germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types, according to study results.

First-line pembrolizumab remained effective, safe and noninferior to chemotherapy among certain patients with PD-L1-positive advanced gastric, gastroesophageal junction cancer, according to follow-up results of the KEYNOTE-062 study.